{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:14:12Z","timestamp":1739423652299,"version":"3.37.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,12]]},"DOI":"10.7759\/cureus.78884","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:25:56Z","timestamp":1739348756000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed Recovery of a Disintegrin-Like and Metalloproteinase With Thrombospondin Type 1 Motif 13 (ADAMTS13) Activity in Immune Thrombotic Thrombocytopenic Purpura Treated With Caplacizumab and Rituximab"],"prefix":"10.7759","author":[{"given":"Yusuke","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneo","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp053024","article-title":"Thrombotic thrombocytopenic purpura","volume":"354","author":"George JN","year":"2006","unstructured":"George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006, 354:1927-35. 10.1056\/NEJMcp053024","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03657-0","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto M","year":"2023","unstructured":"Matsumoto M, Fujimura Y, Wada H, et al.. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023, 118:529-46. 10.1007\/s12185-023-03657-0","journal-title":"Int J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock GA","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991, 325:393-7. 10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01696619","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange","volume":"70","author":"Pereira A","year":"1995","unstructured":"Pereira A, Mazzara R, Monteagudo J, et al.. Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995, 70:319-23. 10.1007\/BF01696619","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini CL","year":"2010","unstructured":"Balduini CL, Gugliotta L, Luppi M, et al.. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010, 89:591-6. 10.1007\/s00277-009-0877-5","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03495-6","article-title":"The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study","volume":"117","author":"Miyakawa Y","year":"2023","unstructured":"Miyakawa Y, Imada K, Ichikawa S, et al.. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study. Int J Hematol. 2023, 117:366-77. 10.1007\/s12185-022-03495-6","journal-title":"Int J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi F","year":"2021","unstructured":"Peyvandi F, Cataland S, Scully M, et al.. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021, 5:2137-41. 10.1182\/bloodadvances.2020001834","journal-title":"Blood Adv"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully M","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, et al.. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019, 380:335-46. 10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly BS","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017, 129:2836-46. 10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully M","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011, 118:1746-53. 10.1182\/blood-2011-03-341131","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024023862","article-title":"ADAMTS13 recovery in caplacizumab-treated TTP","volume":"143","author":"L\u00e4mmle B","year":"2024","unstructured":"L\u00e4mmle B. ADAMTS13 recovery in caplacizumab-treated TTP. Blood. 2024, 143:1785-6. 10.1182\/blood.2024023862","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012451","article-title":"Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP","volume":"8","author":"Saito K","year":"2024","unstructured":"Saito K, Sakai K, Kubo M, et al.. Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP. Blood Adv. 2024, 8:2151-9. 10.1182\/bloodadvances.2023012451","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi PK","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, et al.. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017, 4:157-64. 10.1016\/S2352-3026(17)30026-1","journal-title":"Lancet Haematol"},{"key":"ref14","article-title":"Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies","volume":"101","author":"Bresin E","year":"2009","unstructured":"Bresin E, Gastoldi S, Daina E, et al.. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009, 101:233-8.","journal-title":"Thromb Haemost"},{"key":"ref15","article-title":"Rituximab","author":"Hanif N","year":"2024","unstructured":"Hanif N, Anwer F. Rituximab. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13182","article-title":"Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma","volume":"55","author":"Isonishi A","year":"2015","unstructured":"Isonishi A, Bennett CL, Plaimauer B, Scheiflinger F, Matsumoto M, Fujimura Y. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015, 55:2321-30. 10.1111\/trf.13182","journal-title":"Transfusion"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-024-00642-3","article-title":"Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2\/3 study in Japan","volume":"22","author":"Imada K","year":"2024","unstructured":"Imada K, Miyakawa Y, Ichikawa S, et al.. Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2\/3 study in Japan. Thromb J. 2024, 22:72. 10.1186\/s12959-024-00642-3","journal-title":"Thromb J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng XL","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, et al.. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020, 18:2496-502. 10.1111\/jth.15010","journal-title":"J Thromb Haemost"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022725","article-title":"ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy","volume":"143","author":"Mingot-Castellano ME","year":"2024","unstructured":"Mingot-Castellano ME, Garc\u00eda-Candel F, Mart\u00ednez-Nieto J, et al.. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy. Blood. 2024, 143:1807-15. 10.1182\/blood.2023022725","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340823-delayed-recovery-of-a-disintegrin-like-and-metalloproteinase-with-thrombospondin-type-1-motif-13-adamts13-activity-in-immune-thrombotic-thrombocytopenic-purpura-treated-with-caplacizumab-and-rituximab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:25:57Z","timestamp":1739348757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340823-delayed-recovery-of-a-disintegrin-like-and-metalloproteinase-with-thrombospondin-type-1-motif-13-adamts13-activity-in-immune-thrombotic-thrombocytopenic-purpura-treated-with-caplacizumab-and-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.78884","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}